Asano and colleagues demonstrated an increased surface expression of PD-1 in Tregs during in vitro expansion in mice (with recombinant IL-2) and in vivo expansion using low-dose IL-2 in mice as well as human GvHD patients (51). This evidence concerns the gene IL2 and graft versus host disease.